Skip to main content
. Author manuscript; available in PMC: 2024 Dec 3.
Published in final edited form as: Clin Cancer Res. 2024 Jun 3;30(11):2444–2451. doi: 10.1158/1078-0432.CCR-23-2928

Figure 2. Prognostic significance of pretreatment cfDNA concentration.

Figure 2.

Survival analysis in patients with (A, B) hormone receptor-positive/HER2-negative (HR+HER2−) and (C) triple-negative breast cancer (TNBC) stratified into two groups, high vs. low cfDNA-shedders, using the median cfDNA concentration as the cutoff. The survival endpoint was distant recurrence-free survival (DRFS). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using univariable Cox regression analysis. P values were calculated using the Wald test. The forest plot in B shows HRs and 95% CIs for patients with HR+HER2− breast cancer, estimated from a multivariable Cox regression model that included cfDNA (cfDNA) concentration at pretreatment (T0), adjusted for circulating tumor DNA (ctDNA) status at pretreatment (T0) and residual cancer burden (RCB).